Moderna, Rovi sign ingredients production deal
Moderna has expanded its agreement with Rovi, a Spanish contract drugmaker, to produce active ingredients for its COVID-19 vaccine in addition to a previous fill and finish agreement. Rovi plans to boost its capacity in order to manufacture active ingredients for up to 100 million doses per year.